Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

ABSTRACT: A phase II clinical study of Sintilimab (IBI308) combined with Bevacizumab, Oxaliplatin and Capecitabine regimen as first-line treatment in patients with RAS-mutant and microsatellite stable metastatic colorectal cancer. A total of 25 patients are planned to be enrolled.

DISEASE(S): Metastatic Colorectal Cancer,Ras Mutation,Colorectal Neoplasms,Microsatellite Stable

PROVIDER: 2324330 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR